🔗 Share this article

Given that the United States proceeds with sweeping revisions to its vaccination guidelines, a particular individual has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about Covid shots in the pandemic and has zeroed in on alleged fatalities after COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Program

Public health authorities were set to unveil sweeping changes to the pediatric immunization program earlier this month, aligning the US with Denmark’s national calendar, according to reports – a substantial departure that would put the US out of alignment with many the world with little proof for public health gain. The announcement has been pushed back until the new year.

Instead of the top vaccines chief, Høeg is scheduled to present at the meeting. She was recently named interim head of the FDA’s CDER, the fifth individual to lead the office this calendar year.

A New Direction at the FDA

This interim role may indicate a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for halting specific pediatric immunization guidelines in the US in order to be more in line with Denmark, a nation with nationalized medicine and a population approximately the size of the state of Wisconsin.

In her initial public appearances, she has continued to focus on immunizations – typically the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

Høeg has no obvious track record in pharmaceutical research, approval processes or management, which has been typical for former leaders of the CBER. She has been employed at the FDA as a top consultant to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for running the drug-regulation department, remarked Jonathan Howard. “She has not conducted a scientific study. She lacks experience in leading a major agency. She is not an expert in industry regulation.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, noted Janet Woodcock. “Objectively, she lacks the sort of resume that prior appointees who headed the center have had.”

This division has an immense portfolio at the agency, Woodcock emphasized.

“Everybody just zeroes in on the new drug program, but the off-patent medication office clears thousands of generic drugs. There’s a biosimilars division, non-prescription drug unit and so forth, and each of these must be supervised,” Dr. Woodcock explained. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a substantial management aspect to the job, which supervises in excess of 5,000 staff members. “It’s a huge leadership role, if you perform it correctly,” the former official added.

Response and Disputed Programs

In response to questions about Høeg’s credentials and whether this assignment represents increased cooperation among FDA leaders on vaccines, a representative said that the “questions are based on incorrect assumptions”.

“Her experience is consistent with the duties of her job,” the spokesperson said, pointing to the period Høeg spent counseling the agency head on “drug safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the commissioner’s recently launched fast-track approval initiative, a contentious one-day medication authorization process that reportedly worried her former heads. “How are these medications being picked for this fast-track system? Who makes the decisions?” Dr. Howard said. “There is a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he said, “the agency appears to be shifting towards less stringent rules of most medications, except for vaccines.”

Public Track Record on Immunizations

With immunizations, Høeg has a more established, if concerning, past, some experts observe. She released a study using unconfirmed volunteer-provided data to assess the rate of myocarditis after Covid vaccination. She counseled the state of Florida top health official Joseph Ladapo, who allegedly have altered data to suggest Covid vaccines are riskier than they are.

Among her “policy goals” for the new federal leadership included revising guidelines for recently developed shots and ending “non-essential” vaccines, she remarked post-election on a online show. At the FDA, Høeg has allegedly proposed preventing teenage boys from getting COVID-19 vaccines.

“She’s an thorough ideologue who starts off with her conclusions and works backwards to accommodate the science in a extremely misleading, dishonest fashion,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg aligned with other dissenters, {like|